Intermittent Androgen Deprivation with Goserelin and Flutamide for Prostate Cancer: a Pilot Study.
- Author:
Seong Soo JEON
1
;
Han Yong CHOI
Author Information
1. Department of Urology, Sung Kyun Kwan University, College of Medicine, Samsung Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Prostate neoplasm;
Intermittent androgen deprivation;
Prostate-specific antigen;
Flutamide;
Goserelin
- MeSH:
Flutamide*;
Goserelin*;
Humans;
Medical Records;
Pilot Projects*;
Prostate*;
Prostate-Specific Antigen;
Prostatic Neoplasms*
- From:Korean Journal of Urology
1999;40(10):1295-1300
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The purpose of this study was to evaluate the feasibility of using intermittent androgen deprivation(IAD) in patients with prostate cancer. MATERIALS AND METHODS: We reviewed the medical records of 29 patients treated with IAD for prostate cancer. Androgen deprivation with goserelin and flutamide was continued for at least 4 months after serum prostate specific antigen(PSA) became undetectable or a nadir level was reached. Medication was then discontinued until serum PSA reached a predetermined level. This cycle of treatment was repeated until there was evidence of androgen independence. RESULTS: Twenty-one patients completed the on-treatment during cycle 1, with a median time to PSA nadir of 3 months. Nine patients completed cycle 1 with a median time of off-treatment of 11 months(38% of a treatment cycle). Eight patients continued the off-treatment during cycle 1 for 1+ to 8+ months. During cycle 2, 3 patients achieved a PSA nadir in a median time of 3.5 months. While off treatment, most patients reported reduction of symptoms associated with androgen suppression. CONCLUSIONS: IAD is a feasible alternative for continuous androgen deprivation for treatment of prostate cancer. It also results in the reducion of toxicity, cost of treatment, and possibly a delay in tumor progression.
